| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041504423 |
| P356 | DOI | 10.1046/J.1523-1755.2002.00277.X |
| P698 | PubMed publication ID | 11918743 |
| P5875 | ResearchGate publication ID | 11445465 |
| P50 | author | Kevin J McCarthy | Q59196467 |
| P2093 | author name string | John Hardwick Johnson | |
| Robert Earl Routh | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mesangial cell | Q3331086 |
| P304 | page(s) | 1365-1376 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro | |
| P478 | volume | 61 |
| Q34210856 | Activation of PPARs α, β/δ, and γ Impairs TGF-β1-Induced Collagens' Production and Modulates the TIMP-1/MMPs Balance in Three-Dimensional Cultured Chondrocytes. |
| Q34551882 | Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. |
| Q36577073 | Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection |
| Q40251913 | Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). |
| Q46967291 | Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria |
| Q40705671 | Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells |
| Q40692103 | In vitro matrix assembly induced by critical assembly concentration (CAC). |
| Q51006984 | Leprecan distribution in the developing and adult kidney. |
| Q37723232 | Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice |
| Q36906818 | MicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPARγ, and its In Vivo Knockdown Prevents Progression of Diabetic Nephropathy |
| Q46952714 | Molecular bases of diabetic nephropathy |
| Q38121751 | Molecular basis of organ fibrosis: potential therapeutic approaches |
| Q46252518 | PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta |
| Q36326399 | PPAR-gamma agonists and diabetic nephropathy |
| Q46830543 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis |
| Q41879222 | PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis |
| Q46484275 | PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose |
| Q37072216 | PPARs and the kidney in metabolic syndrome |
| Q44618359 | Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity |
| Q31137196 | Proteomic analysis of S-nitrosylated proteins in mesangial cells |
| Q34103484 | Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells |
| Q90242473 | Targeting metabolic dysregulation for fibrosis therapy |
| Q83283496 | The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy |
| Q40561968 | The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells |
| Q35677086 | hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists |
Search more.